Mohammed Boulhaouaa,
Tibor Pasinszki*b,
Ana Torviscoc,
Rita Oláh-Szabód,
Szilvia Bőszed and
Antal Csámpai*e
aELTE Eötvös Loránd University, Institute of Chemistry, Department of Inorganic Chemistry, H-1117 Budapest, Hungary
bFiji National University, College of Engineering Science and Technology, Department of Chemistry, P.O.Box 3722, Samabula, Suva, Fiji. E-mail: tibor.pasinszki@fnu.ac.fj
cGraz University of Technology, Institute of Inorganic Chemistry, Stremayrgasse 9/V, 8010 Graz, Austria
dMTA-ELTE Research Group of Peptide Chemistry, Pázmány P. sétány 1/A, H-1117 Budapest, Hungary
eELTE Eötvös Loránd University, Institute of Chemistry, Department of Organic Chemistry, H-1117 Budapest, Hungary. E-mail: antal.csampai@ttk.elte.hu
First published on 25th August 2021
Chemotherapy is an indispensable tool to treat cancer, therefore, the development of new drugs that can treat cancer with minimal side effects and lead to more favorable prognoses is of crucial importance. A series of eleven novel 1,2,4-thiadiazoles bearing erlotinib (a known anticancer agent), phenylethynyl, ferrocenyl, and/or ferrocenethynyl moieties were synthesized in this work and characterized by NMR, IR and mass spectroscopies. The solid-phase structures were determined by single-crystal X-ray diffraction. Partial isomerisation of bis(erlotinib)-1,2,4-thiadiazole into its 1,3,4-thiadiazole isomer, leading to the isolation of a 3:2 isomer mixture, was observed and a plausible mechanism for isomerisation is suggested. The in vitro cytostatic effect and the long-term cytotoxicity of these thiadiazole-hybrids, as well as that of erlotinib, 3,5-dichloro-1,2,4-thiadiazole and 3,5-diiodo-1,2,4-thiadiazole were investigated against A2058 human melanoma, HepG2 human hepatocellular carcinoma, U87 human glioma, A431 human epidermoid carcinoma, and PC-3 human prostatic adenocarcinoma cell lines. Interestingly, erlotinib did not exhibit a significant cytostatic effect against these cancer cell lines. 1,2,4-Thiadiazole hybrids bearing one erlotinib moiety or both an iodine and a ferrocenethynyl group, as well as 3,5-diiodo-1,2,4-thiadiazole demonstrated good to moderate cytostatic effects. Among the synthesized 1,2,4-thiadiazole hybrids, the isomer mixture of bis-erlotinib substituted 1,2,4- and 1,3,4-thiadiazoles showed the most potent activity. This isomer mixture was proven to be the most effective in long-term cytotoxicity, too. 3,5-Diiodo-1,2,4-thiadiazole and its hybrid with one erlotinib fragment were also highly active against A431 and PC-3 proliferation. These novel compounds may serve as new leads for further study of their antiproliferative properties.
Hybrid anticancer agents possess real potential to overcome certain disadvantages of single cancer drugs, including MDR and adverse effects; therefore, based on this promising strategy, the aim of the present work was to develop novel anticancer agents for the potential treatment of human glioblastoma,8 melanoma,9 non-melanoma skin carcinoma,10,11 hepatocarcinoma12 and prostatic adenocarcinoma13 by coupling the pharmacophore 1,2,4-thiadiazole moiety to ethynylferrocene and to the known anticancer agent erlotinib, (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine) (1). Thiadiazoles are versatile synthetic scaffolds possessing a wide range of biological activities.14–16 1,2,4-Thiadiazole derivatives have been shown to exhibit anticancer activity against e.g., breast, lung, colon, and ovarian cancerous cells.15,16 Ferrocene-based compounds have been reported to be active against several cancer cell lines, including e.g., breast, lung, ovarian, melanoma, glioblastoma, and colon cancer.17–19 Erlotinib is an approved anticancer drug, and currently used for the treatment of locally advanced or metastatic non-small-cell lung cancer and pancreatic cancer.20,21 In this context, one of the aims of the present work was an in vitro test of the antiproliferative activity of 1 on human malignant cell lines A2058 (melanoma), A431 (epidermoid carcinoma), U87 (glioma), HepG2 (hepatocellular carcinoma), and PC-3 (prostatic adenocarcinoma) followed by an attempt to produce novel erlotinib-containing hybrids of enhanced efficiency. In this regard, prompted by the aforementioned well-documented activity profile of anticancer 1,2,4-thiadiazoles described to date and utilising Sonogashira reaction as an obvious feasible method, 1 was coupled with 3,5-dihalo-substituted 1,2,4-thiadiazoles (dichloro: 2, diiodo: 3) affording novel molecular hybrids. In order to estimate the contribution of the bulky, yet highly polar and functionalised erlotinib fragment to cytotoxicity in the design of additional hybrids, the quinazolinamine fragments were simplified to phenylethynyl groups, which were then further modified by replacing phenyl substituent(s) with three-dimensional and redox-active ferrocenyl group(s) of enhanced lipophilicity. Accordingly, in this paper, we report the synthesis and structural characterisation of a selection of novel thiadiazole-hybrids (4–15: Schemes 1 and 2) along with their evaluation in antiproliferative studies carried out in vitro on A2058, A431, U87, HepG2 and PC-3 cells using 1, 2 and 3, as controls.
Fig. 1 Acceptor orbitals of lowest energy levels in 3,5-dihalo-1,2,4-thiadiazoles 2 and 3 obtained by B3PW91 DFT functional22 using DGTZVP basis set.23 |
It is of interest that Sonogashira coupling reactions aiming at the synthesis of bis-erlotinib derivative 14 led to the isolation of an approximately 3:2 mixture of the targeted product and its isomer 15 featuring a [1,3,4]thiadiazole-centered symmetrical constitution (Scheme 2), as detected and identified by extended NMR studies including 2D-HSQC and 2D-HMBC measurements.
The formation of 15 can be interpreted in terms of the partial isomerisation of 14, the primary product of the Sonogashira reaction when it was conducted at 95 °C for prolonged reaction times (for 15 h by Procedure A and for 20 h by Procedure B) representing harsher conditions than those employed for the other conversions investigated in our research that were conducted at 50–80 °C for 6–12 h (see: Experimental). The mechanism proposed by us for transformation 14 → 15 involves the initial π-complexation of a Pd(0) species with the alkyne residue at C5-position and a concomitant coordination of a Cu(I) species to the N2 ring atom to construct bimetallic cationic complex 16a (Scheme 2a). By means of the coordination of the Cu(I) centre to the proximal S1 atom and the development of a bonding interaction between alkyne-coordinated Pd(0) and the skeletal N4 atom in 16a, the two metal centres promote the fission of the S1–N2 and C3–N4 bonds proceeding via transition state TS(16-17) to generate a five-membered palladacycle intermediate with pending tricoordinated copper(I)-centre (17). In the subsequent steps involving separated intermediates 18 and 19, complex 17 is supposed to isomerize to complex 20 featuring a N–Cu–N coordination mode. To terminate the rearrangement process, 20 undergoes electrocyclisation through a transition state TS(20-21b), with a quasi-six membered ring, finally constructing 21b stabilized by a Cu(I)⋯Pd(0) interaction as evidenced by DFT calculations performed on simplified models (Fig. 2). Regarding the initial elementary step it must be noted here that – according to the aforementioned theoretical studies – the cleavage of S1–N2 and C3–N4 bonds in regioisomer complex 16b, stabilized by Cu(I)⋯Pd(0) interaction, is not feasible to advance the process towards a complete ring transformation. The presented view about the mechanism gained support from the results of DFT modelling carried out at B3PW91/DGTZVP level of theory for the simplified structures of the assumed intermediates (16a,b*, 17*, 18*, 19*, 20*, 21a,b*) and transition states [TS(16*-17*) and TS(20*-21b*)] comprising single ethynyl group and appropriately coordinated neutral and cationic metal-containing simplified fragments PdPH3 and CuPH3, respectively (Scheme 2b). The intermediates and transition states were identified as local minima and first order saddle points, respectively, on the potential energy surface (PES). Transition states were localized by QST2 method.24 The energetic profile of the overall transformation was characterized by the changes in Gibbs free energy (G) accompanying the assumed elementary steps and the activation barriers of the ring opening and ring closing processes. The free energy values of optimised structures were obtained by correcting the computed total energy with zero-point vibrational energy (ZPE) and thermal corrections calculated at the same level. In the initial stage of the conversion, the fission of the 1,2,4-thiadiazole ring was disclosed as the rate-limiting endothermic elementary step (ΔG = +39.1 kcal mol−1) proceeding via a high barrier (ΔG‡ = 60.0 kcal mol−1) followed by an endothermic isomerization of the palladacycle intermediate (17* → 20*) taking place by the copper-centred decoordination–coordination sequence via separated Cu(I)- and Pd(0) fragments 18* and 19*. Finally, 20* was identified as the intermediate which can be connected by transition state TS(20*-21b*) exclusively with 21b* in accord with qualitative structural considerations, in the 1,3,4-thiadiazole-forming cyclization. The multistep isomerization of bimetal complex 16a* into 21b* is an endothermic process as indicated by the change in the free energy calculated for the overall conversion (ΔG = +6.2 kcal mol−1). Moreover, the change in the Gibbs free energy [ΔG(15*-14*) = +14.5 kcal mol−1] calculated for vacuum by modelling simplified metal-free isomer pair 2-ethynyl-1,3,4-thiadiazole(15*)/5-ethynyl-1,2,4-thiadiazole (14*) would suggest that – in general – the transformation of 5-alkynyl-substituted 1,2,4-thiadiazoles into the 1,3,4-thiadiazole counterpart is not a feasible process however, the relative energetics of structures 14 and 15 and their appropriate metal complexes under real experimental conditions with bulky phosphine ligand [P(t-Bu)3] of outstanding donor strength and dimethylformamide as solvent of significant coordination- and solvation ability, might significantly differ from the calculated values allowing the development of an equilibrium system containing 15 as the minor component. In accord with this view, upon further prolongation of the reaction time (24 h) practically no change in the isomer ratio was discernible in the isolated mixture of products 14 and 15.
Finally, the abovementioned Cu(I)⋯Pd(0) contact was disclosed by MO analysis of the simplified models 16b* and 21b*. The enhanced stability of these complexes relative to their coordination isomers 16a* [ΔG(16a*–16b*) = +5.0 kcal mol−1] and 21a* [ΔG(21a*–21b*) = +4.2 kcal mol−1], respectively, can be attributed to this type of interaction which is demonstrated by the delocalisation of two–two bonding orbitals in between the metal centres (Fig. 2). Our attempts to separate 14 from 15 was not successful, therefore the mixture 14/15 was used in biological studies.
Fig. 3 Solid state structure of 4, 5, 8, 10 and 11 established by single crystal X-ray diffraction. All atoms are shown as 30% shaded ellipsoids (C: black, N: blue, S: yellow, Cl: green, Fe: orange). |
Fig. 4 Structure and packing of 6. All atoms are shown as 30% shaded ellipsoids (C: black, N: blue, S: yellow, I: violet, Fe: orange). |
Label | U87 | A2058 | A431 | HepG2 |
---|---|---|---|---|
IC50 (μM) 20 h treatment + 72 h incubation | ||||
1 | >100 | >100 | 78.1 ± 14.4 | >100 |
2 | >50 | 11.3 ± 1.0 | 28.6 ± 5.7 | >50 |
3 | 15.3 ± 0.6 | 20.2 ± 7.9 | 5.5 ± 2.9 | 13.0 ± 1.9 |
4 | >50 | >50 | >50 | >50 |
5 | >50 | >50 | >50 | >50 |
6 | 18.2 ± 6.1 | 17.1 ± 6.5 | 22.0 ± 7.9 | 13.9 ± 3.3 |
7 | >50 | >50 | 19.5 ± 9.3 | >50 |
8 | >50 | >50 | >50 | >50 |
9 | >50 | >50 | 17.4 ± 7.4 | >50 |
10 | 45.0 ± 5.9 | 23.7 ± 10.2 | >50 | 29.4 ± 10.9 |
11 | >50 | 31.8 ± 7.1 | >50 | >50 |
12 | 25.9 ± 4.1 | 20.3 ± 3.9 | 22.9 ± 3.1 | 27.4 ± 5.5 |
13 | 27.0 ± 4.0 | 16.0 ± 6.1 | 5.8 ± 4.1 | 22.9 ± 0.9 |
14/15 | 1.7 ± 0.1 | 1.2 ± 0.2 | 5.6 ± 0.1 | 1.6 ± 0.2 |
IC50 (μM) 72 h treatment | ||||
1 | >10 | >10 | 3.4 ± 2.1 | >10 |
3 | >10 | >10 | 9.3 ± 0.3 | >10 |
13 | >10 | >10 | 6.4 ± 4.2 | >10 |
14/15 | 0.9 ± 0.3 | 1.5 ± 0.4 | 1.1 ± 0.6 | 3.4 ± 1.4 |
IC50 (μM) 3 × 24 h treatment | ||||
1 | 8.9 ± 0.5 | >10 | 2.4 ± 0.3 | >10 |
3 | >10 | >10 | 6.0 ± 1.0 | >10 |
13 | >10 | 9.6 ± 0.2 | 4.6 ± 2.9 | >10 |
14/15 | 0.7 ± 0.4 | 1.4 ± 0.4 | 1.0 ± 0.3 | 2.7 ± 1.2 |
The long term cytotoxicity (cytotoxic activity; the direct killing of cancer cells) of 1 and three thiadiazole hybrids (3, 13, and 14/15), that were effective in cytostasis experiments, was also studied on previously used four cell lines. Two setups of experiments were conducted: cells were treated with thiadiazole derivatives for 72 h (protocol 2) or treated 3-times with compounds, without interstitial washing, for 24 h (protocol 3). 1 produced an effect on A431 cells after 72 hours, and on A431 and U87 cells following the 3 × 24 h treatment. 14/15 was the most effective in these experiments too.
Currently, the combination of dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib are approved for treating melanoma.9 Although there is a rapid early response and high response rate to these combined agents, the progression of disease occurs at a median of eleven months, due to drug resistance; therefore, novel drugs and drug combinations are needed.26 Thiadiazole-hybrids might be potential candidates. A2058 cells are found to be more sensitive to 14/15 than to vemurafenib (IC50 = 5.93 μM).27 If chemotherapy is applied for the treatment of non-melanoma skin cancers, 5-fluorouracil (e.g. in the form of its oral prodrug capecitabine or in creams) may be used.10,11 5-Fluorouracil has an IC50 value of 47.02 μM for A431 cells.28 Thiadiazole derivatives 2, 3, 6, 7, 9, 12, 13 and 14/15 exhibit smaller IC50 values therefore are more toxic to A431 cells than this compound. Application of temozolomide in combination with radiotherapy has become a standard of care for glioblastoma multiforme patients; the drug, however, is very expensive and the survival rate of patients is less than two years.8 Sorafenib is currently the only effective first-line drug for the treatment of advanced hepatocellular carcinoma patients, however, its efficacy is short owing to the development of resistant cells.12 New drugs are therefore required. 3 and thiadiazole-hybrids are much more effective on U87 cell line than the currently used chemotherapeutic agent temozolomide (IC50 = 134.97 μM (ref. 29)) and 14/15 is more effective on HepG2 than Sorafenib (IC50 = 9.70 μM (ref. 30)). Docetaxel is the mainstay of chemotherapy for prostate cancer with cabazitaxel as second-line drug.13 1 has also been investigated in clinical trials as a potential chemotherapeutic agent for prostate cancer treatment.31 Nine of the synthesized thiadiazole-hybrids proved to be more effective on PC-3 cells than 1 (Table 2). Thiadiazole derivatives studied in this work, especially compounds 14/15, 13, and 3 with the lowest IC50 values, may serve as new leads for further study of their antiproliferative properties. We note that the cytostatic effect of these compounds, especially that of 14/15, is outstanding compared to the reference anticancer drug 1.
Label | PC-3 | Label | PC-3 |
---|---|---|---|
IC50 (μM) 20 h treatment + 72 h incubation | |||
1 | >50 | 8 | 22.7 ± 2.4 |
2 | >50 | 9 | >50 |
3 | 3.1 ± 0.3 | 10 | 16.9 ± 3.7 |
4 | >50 | 11 | 38.0 ± 4.2 |
5 | >50 | 12 | 7.7 ± 2.6 |
6 | 10.7 ± 0.7 | 13 | 4.5 ± 0.5 |
7 | 37.6 ± 7.5 | 14/15 | 0.4 ± 0.1 |
Compound | 4 | 6 | 5 | 10 | 11 | 8 |
---|---|---|---|---|---|---|
a Mo Kα (λ = 0.71073 Å). R1 = Σ/|Fo| − |Fc|/|Σ|Fd; wR2 = [Σw(Fo2 − F22)2/Σw(Fo2)2]1/2. | ||||||
Formula | C12H9ClFeN2S | C14H9FeIN2S | C14H9ClFeN2S | C22H14FeN2S | C22H14FeN2S | C26H18Fe2N2S |
Fw (g mol−1) | 304.57 | 420.04 | 328.59 | 394.26 | 394.26 | 502.18 |
a (Å) | 9.7781(9) | 12.0436(10) | 7.4925(19) | 11.3950(11) | 7.4489(12) | 9.8936(6) |
b (Å) | 21.088(2) | 14.8358(12) | 7.5319(16) | 19.7263(18) | 7.4086(12) | 8.8451(5) |
c (Å) | 11.3518(10) | 7.5107(6) | 11.801(2) | 7.6124(8) | 32.085(5) | 23.0850(13) |
α (°) | 90 | 90 | 102.546(17) | 90 | 90 | 90 |
β (°) | 99.460(4) | 91.413(4) | 103.317(17) | 92.122(6) | 93.571(8) | 99.728(5) |
γ (°) | 90 | 90 | 92.575(18) | 90 | 90 | 90 |
V (Å3) | 2308.9(4) | 1341.58(19) | Block, orange | 1710.0(3) | 1767.2(5) | 1991.1(2) |
Z | 8 | 4 | 2 | 4 | 4 | 4 |
Crystal size (mm) | 0.08 × 0.08 × 0.07 | 0.04 × 0.04 × 0.01 | 0.14 × 0.13 × 0.10 | 0.05 × 0.04 × 0.04 | 0.05 × 0.05 × 0.01 | 0.27 × 0.19 × 0.15 |
Crystal habit | Block, red | Plate, orange | Block, orange | Block, red | Plate, red | Block, red |
Crystal system | Monoclinic | Monoclinic | Triclinic | Monoclinic | Monoclinic | Monoclinic |
Space group | P21/c | P21/c | P | P21/c | P21/c | P21/c |
dcalc (mg m−3) | 1.752 | 2.080 | 1.734 | 1.531 | 1.482 | 1.675 |
μ (mm−1) | 1.69 | 1.69 | 1.56 | 1.01 | 0.98 | 1.58 |
T (K) | 100(2) | 100(2) | 100(2) | 100(2) | 100(2) | 100(2) |
2θ range (°) | 2.3–33.2 | 3.4–32.4 | 2.8–33.3 | 2.9–33.2 | 2.5–33.2 | 2.5–33.2 |
F(000) | 1232 | 808 | 332 | 808 | 808 | 1024 |
Tmin, Tmax | 0.556, 0.741 | 0.522, 0.747 | 0.622, 0.747 | 0.632, 0.747 | 0.372, 0.747 | 0.587, 0.747 |
Rint | 0.056 | 0.117 | 0.048 | 0.102 | 0.25 | 0.106 |
No. of measured, independent and observed [I > 2 s(I)] reflections | 186019, 8831, 7915 | 31160, 2340, 1838 | 39429, 2191, 2128 | 48371, 3001, 2421 | 3092, 3092, 2241 | 196783, 7626, 6753 |
Independent reflections | 8831 | 2340 | 2191 | 3001 | 3092 | 7626 |
No. of parameters, restraints | 307, 0 | 173, 0 | 172, 0 | 235, 0 | 235, 0 | 299, 0 |
Δmax, Δmin (e Å−3) | 0.69, −0.35 | 0.61, −0.60 | 0.34, −0.18 | 0.28, −0.33 | 0.60, −0.93 | 0.60, −0.60 |
R1, wR2 (all data) | R1 = 0.0314 | R1 = 0.0503 | R1 = 0.0177 | R1 = 0.0499 | R1 = 0.1247 | R1 = 0.0343 |
wR2 = 0.0679 | wR2 = 0.0669 | wR2 = 0.0445 | wR2 = 0.0750 | wR2 = 0.1837 | wR2 = 0.0709 | |
R1, wR2 (>2σ) | R1 = 0.0255 | R1 = 0.0297 | R1 = 0.0168 | R1 = 0.0317 | R1 = 0.0862 | R1 = 0.0287 |
wR2 = 0.0630 | wR2 = 0.0574 | wR2 = 0.0437 | wR2 = 0.0649 | wR2 = 0.1693 | wR2 = 0.0681 |
Finally, it is of crucial importance to provide evidence for that the intact hybrid molecules rather than any of their decomposition-derived fragments are the species which induce evolution of the antiproliferative effect in the course of the biological assays employing long-term treatment of the cells. According to our first observations the synthesized compounds in solid state were stable at ambient conditions; decomposition or colour change were not observed over a couple of months. Moreover, these compounds were not sensitive to air, moisture or light when handled at ambient conditions, and can generally be stored in closed vial at room temperature in the dark without decomposition as proved by IR- and MS measurements. The long-term stability of the compounds in solution was also checked by registering their 1H-NMR spectra in DMSO-d6 after 72 h following the preparation of the liquid samples stored under air at room temperature. Supporting our abovementioned observations regarding the stability of the novel hybrids, their spectra did not show any detectable change in their structures, although the solvent was contaminated with a substantial amount of HDO.
The 1H- and 13C-NMR spectra of the synthesized compounds were recorded on a Bruker DRX-500 MHz spectrometer at 500 MHz and 125 MHz, respectively, at room temperature using the deuterium signal of the solvent as the lock and tetramethylsilane (TMS) as the internal standard. The assignment of all 1H- and 13C-NMR data necessary for exact structural elucidation of the compounds was based on the cross-peak correlations discernible in 2D-HSQC and HMBC spectra obtained by standard Bruker pulse programs. Mass spectroscopic measurements were done using an Esquire 3000 + (Bruker) ion trap mass spectrometer and electrospray ionization (ESI). Exact mass measurements for samples 12, 13, and 14/15 were taken on a high-resolution Waters Q-Tof Premier mass spectrometer equipped with an ESI ion source (3000 V capillary voltage, 350 °C desolvation temperature, 650 L h−1 nitrogen as desolvation gas). The samples were dissolved in methanol (10 μg mL−1) and 5 μL were injected in a continuous flow of methanol (400 μL min−1, contain 0.1% formic acid). Each compound was analysed twice, the first spectrum was recorded without consideration of temperature variations. The second measurement was processed after the correction of temperature variations with a reference compound.
Spectroscopic data: MS: 305.0 m/z [M + 1+]. IR (neat, ATR): 3090 (w), 2923 (w), 2853 (vw), 1516 (s), 1430 (s), 1385 (w), 1350 (vw), 1235 (vs), 1201 (m), 1104 (m), 1064 (w), 1028 (w), 999 (m), 927 (vw), 822 (m), 752 (w), 716 (m), 693 (m), 641 (w), 507 (m), 481 (m) cm−1. 1H NMR (CDCl3): 4.89 (br ∼ s, 2H, H-8,11); 4.57 (br ∼ s, 2H, H-9,10); 4.14 (s, 5H, η5-C55) ppm; 13C NMR (CDCl3): 192.8 (C-5); 157.0 (C-3); 73,4 (C-7); 72.0 (C-9,10), 70.9 (η5-C5H5); 68.8 (C-8,11) ppm.
Spectroscopic data of 5: MS: 328.9 m/z [M + 1+]. IR (neat, ATR): 3095 (vw), 2955 (vw), 2922 (w), 2854 (vw), 2200 (vs), 1501 (m), 1420 (s), 1381 (m), 1355 (w), 1259 (w), 1228 (vs), 1116 (s), 1028 (m), 1000 (w), 943 (m), 818 (s), 731 (w), 682 (w), 623 (vw), 541 (w), 495 (s), 456 (m) cm−1. 1H-NMR (CDCl3): 4.61 (t, J = 1.8 Hz, 2H, H-10,13); 4.40 (t, J = 1.8 Hz, 2H, H-11,12); 4.26 (s, 5H, η5-C5); 13C-NMR (125 MHz): 171.7 (C-5); 157.5 (C-3); 107.6 (C-8); 75.7 (C-7); 72.6 (C-11,12); 70.8 (C-10,13); 70.5 (η55H5); 60.5 (C-9) ppm.
Spectroscopic data of 6: MS: 419.9 m/z [M+]. IR (neat, ATR): 3097 (vw), 2959 (vw), 2923 (vw), 2857 (vw), 2199 (vs), 1495 (w), 1407 (m), 1373 (w), 1340 (w), 1252 (w), 1187 (s), 1115 (m), 1029 (w), 1002 (vw), 923 (w), 888 (w), 822 (m), 789 (w), 727 (vw), 666 (vw), 625 (vw), 537 (vw), 488 (m) cm−1. 1H-NMR (CDCl3): 4.60 (t, J = 1.8 Hz, 2H, H-10,13); 4.39 (t, J = 1.8 Hz, 2H, H-11,12); 4.25 (s, 5H, η5-C55); 13C-NMR (CDCl3): 171.2 (C-5); 117.6 (C-3); 107.9 (C-8); 75.0 (C-7); 72.5 (C-11,12); 70.8 (C-10,13); 70.5 (η5-5H5); 60.5 (C-9) ppm.
Procedure B: a mixture of 2 (1 mmol, 0.16 g) or 3 (1 mmol, 0.34 g), ethynylferrocene (3 mmol, 0.63 g), Pd(PPh3)2Cl2 (3 mol%, 0.02 g), CuI (3 mol%, 0.006 g), and diisopropylamine (3 mmol, 0.3 g) in freshly distilled toluene (5 mL) was stirred at 70 °C for 12 h under a nitrogen atmosphere. The reaction was monitored by TLC using hexane/ethyl acetate (95:5) as the eluent. After completion of the reaction, the resulting mixture was cooled to room temperature, and the solvent was evaporated in vacuo. The crude material was dissolved with chloroform, washed with water, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using hexane/ethyl acetate (95:5) as eluent to afford the pure dark red crystalline product 8 (yield: 0.33 g, 66%). Mp: 218–220 °C.
Spectroscopic data: MS: 503.0 m/z [M + 1+]. IR (neat, ATR): 3102 (vw), 2956 (w, sh), 2920 (s), 2851 (m), 2202 (vs), 1480 (m), 1413 (s), 1367 (w), 1283 (w), 1255 (m), 1212 (s), 1109 (s), 1028 (s), 892 (vw), 821 (s), 718 (w), 544 (w), 488 (s), 455 (m), 412 (vw) cm−1. 1H-NMR (CDCl3): 4.61 and 4.60 (two partly overlapping t's, J ∼ 2 Hz for each, 4H, H-9,9′,12,12′); 4.40 (two overlapping t's, J = 1.8 Hz, 4H, H-10,10′,11,11′); 4.26 and 4.24 (2 × s, 2 × 5H, 2 × η5-C55); 13C-NMR (CDCl3): 169.1 (C-5); 157.8 (C-3); 105.6 (C-7′); 90.1 (C-7); 79.0 (C-6); 75.7 (C-6′); 72.4 and 72.3 (C-9,9′,10,10′, 11,11′,12,12′); 70.5 and 70.3 (2 × η5-5H5); 62.2 and 61.1 (C-8,8′) ppm.
Spectroscopic data: MS: 595.1 m/z [M + 1+]. IR (neat, ATR): 3094 (vw), 3055 (vw), 2959 (w), 2924 (w), 2855 (vw), 2219 (vs), 1490 (m), 1450 (m), 1397 (m), 1367 (m), 1287 (m), 1217 (s), 1103 (m), 1041 (w), 999 (w), 972 (vw), 914 (vw), 824 (m), 756 (m), 718 (w), 687 (m), 581 (w), 535 (w), 495 (m) cm−1. 1H-NMR (CDCl3): 7.59 (dd, J = 7.8 Hz and 1.8 Hz, 2H, H-13′,15′); 7,45 (tt, J = 7.8 Hz and 1.8 Hz, 1H, H-11′); 7.40 (∼t, J ∼ 8 Hz, 2H, H-10′, 12′); 4.62 (t, J = 1.9 Hz, 2H, H-9,12); 4.30 (t, J = 1.9 Hz, 2H, H-10,11); 4.24 (s, 5H, η5-C55); 13C-NMR (CDCl3): 168.7 (C-5); 157.9 (C-3); 132.3 (C-9′,13′); 130.7 (C-11′); 128.8 (C-10′, 12′); 120.4 (C-8′); 103.2 (C-7′); 90.6 (C-7); 78.9 (C-6′); 78.5 (C-6); 72.4 (C-9,12); 70.3 (η5-5H5); 69.8 (C-10,11); 62.0 (C-8) ppm.
Spectroscopic data: MS: 595.1 m/z [M + 1+]. IR (neat, ATR): 3092 (vw), 3056 (vw), 2923 (vw), 2850 (vvw), 2201 (vs), 1494 (m), 1425 (s), 1292 (m), 1255 (m), 1198 (m), 1117 (m), 1063 (vw), 1030 (m), 1001 (w), 914 (w), 827 (m), 757 (m), 722 (w), 689 (m), 579 (vw), 533 (w), 484 (m) cm−1. 1H-NMR (CDCl3): 7.62 (dd, J = 7.8 Hz and 1.8 Hz, 2H, H-9,13); 7,40 (tt, J = 7.8 Hz and 1.8 Hz, 1H, H-11); 7.36 (∼t, J ∼ 8 Hz, 2H, H-10, 12); 4.61 (t, J = 1.8 Hz, 2H, H-9′,12′); 4.30 (t, J = 1.8 Hz, 2H, H-10′,11′); 4.26 (s, 5H, η5-C55); 13C-NMR (CDCl3): 169.4 (C-5); 157.4 (C-3); 132.3 (C-9,13); 129.8 (C-11); 128.5 (C-10, 12); 121.2 (C-8); 105.9 (C-7′); 89.2 (C-7); 82.0 (C-6); 75.7 (C-6′); 72.4 (C-9′,12′); 70.6 (C-10′,11′); 70.5 (η5-5H5); 61.0 (C-8) ppm.
Spectroscopic data of 12: MS: 511.7 m/z [M + 1+]; HR-MS: 512.1155 m/z (most abundant [M + 1+] isotopic peak; theoretical value: 512.1159). IR (neat, ATR): 3485 (w), 3321 (w), 3115 (w), 3073 (w), 2979 (vw), 2923 (w), 2882 (w), 2817 (w), 2205 (m), 1625 (m), 1573 (m), 1509 (m), 1460 (m), 1428 (s), 1391 (w), 1366 (w), 1282 (w), 1222 (s), 1118 (m), 1100 (m), 1065 (w), 1022 (m), 959 (w), 929 (m), 894 (w), 861 (m), 786 (m), 681 (m), 616 (w), 576 (m), 550 (w), 465 (w) cm−1. 1H-NMR (DMSO-d6): 9.51 (s, 1H, H-15); 8.49 (s, 1H, H-18); 8.25 (br s, 1H, H-14); 7.95 (br d, J ∼ 8 Hz, 1H, H-12); 7.65 (s, 1H, H-24); 7.50 (t, J ∼ 8.0 Hz, 1H, H-11); 7.44 (br d, J = 8 Hz, 1H, H-10); 7.20 (s, 1H, H-21); 4.26 (m, 4H, H-26,27); 3.75 and 3.71 (two partly overlapping t's, J ∼ 6 Hz for each, 2 × 2H, H-28,29); 3.33 and 3.31 (2 × s, 2 × 3H, H-30,31). 13C-NMR (DMSO-d6): 171.0 (C-5); 157.9 (C-3); 156.5 (C-16); 154.3 (C-22); 153.2 (C-18); 148.8 (C-23); 147.3 (C-20); 140.6 (C-13); 129.9 (C-11); 127.3 (C-10); 125.4 (C-14); 125.1 (C-12); 119.8 (C-9); 109.4 (C-25); 108.6 (C-21); 104.3 (C-8); 103.8 (C-24); 78.3 (C-7); 70.6 and 70.5 (C-26,27); 68.9 and 68.6 (C-28,29); 58.9 (two coalesced lines, C-30,31) ppm.
Spectroscopic data of 13: MS: 603.8 m/z [M + 1+]; HR-MS: 604.0517 m/z (most abundant [M + 1+] isotopic peak; theoretical value: 604.0516). IR (neat, ATR): 3479 (vw), 3318 (vw), 3123 (vw), 3074 (vw), 2919 (m), 2852 (w), 2817 (vw), 2202 (m), 1625 (m), 1575 (m), 1511 (m), 1456 (m), 1426 (s), 1342 (w), 1278 (vw), 1247 (w), 1221 (w), 1181 (m), 1124 (w), 1093 (w), 1065 (w), 1026 (w), 947 (w), 928 (w), 888 (w), 858 (m), 784 (m), 675 (w), 574 (w), 542 (w), 457 (w) cm−1. 1H-NMR (DMSO-d6): 9.51 (s, 1H, H-15); 8.50 (s, 1H, H-18); 8.24 (br s, 1H, H-14); 7.97 (br d J ∼ 8 Hz, 1H, H-12); 7.64 (s, 1H, H-24); 7.50 (t, J ∼ 8.0 Hz, 1H, H-11); 7.42 (br d, J = 8 Hz, 1H, H-10); 7.20 (s, 1H, H-21); 4.26 (m, 4H, H-26,27); 3.75 and 3.71 (two partly overlapping t's, J ∼ 6 Hz for each, 2 × 2H, H-28,29); 3.33 and 3.31 (2 × s, 2 × 3H, H-30,31). 13C-NMR (DMSO-d6): 170.6 (C-5); 156.5 (C-16); 154.3 (C-22); 153.2 (C-18); 148.8 (C-23); 147.3 (C-20); 140.6 (C-13); 132.4 (C-3); 129.9 (C-11); 127.3 (C-10); 125.4 (C-14); 125.1 (C-12); 119.8 (C-9); 109.4 (C-25); 108.6 (C-21); 104.6 (C-8); 103.8 (C-24); 78.0 (C-7); 70.60 and 70.54 (C-26,27); 68.9 and 68.6 (C-28,29); 58.87 and 58.82 (C-30,31) ppm.
Procedure B: a mixture of 2 (1 mmol, 0.16 g) or 3 (1 mmol, 0.34 g), erlotinib (3 mmol, 1.2 g), Pd[P(t-Bu)3]2 (10 mol%, 0.05 g), CuI (10 mol%, 0.02 g) and K3PO4 (3 mmol, 0.64 g) in freshly distilled DMF (3 mL) was stirred vigorously at 95 °C for 20 h under a nitrogen atmosphere. The reaction was monitored by TLC using hexane/ethyl acetate (30:70) as the eluent. After completion of the reaction, the resulting mixture was quenched by water (30 mL), and extracted with chloroform (3 × 20 mL). The combined organic layers were washed with water, dried over anhydrous MgSO4, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using hexane/ethyl acetate (30:70) as eluent to afford the pure white product 14/15 (yield: 0.53 g, 61%). Mp: 132–134 °C.
Spectroscopic data of a ca. 3/2 mixture of 14/15: MS: 869.4 [M + 1+], 435.4 [(M + 2)2+] m/z; HR-MS: 869.3080 m/z (most abundant [M + 1+] isotopic peak; theoretical value: 869.3081). IR (neat, ATR): 3483 (vw), 3447 (vw), 3318 (vw), 3272 (vw), 3063 (vw), 2976 (vw), 2926 (w), 2883 (w), 2820 (w), 2227 (s), 1625 (m), 1576 (m), 1507 (m), 1428 (s), 1391 (m), 1281 (w), 1242 (m), 1212 (m), 1124 (m), 1068 (w), 1028 (m), 933 (w), 894 (vw), 858 (m), 784 (m), 716 (vw), 684 (w), 658 (w), 579 (w), 549 (w), 465 (w) cm−1.
NMR data of 14: 1H-NMR (DMSO-d6): 9.56 (s, 1H, H-14′); 9.53 (s, 1H, H-14); 8.51 (s, 1H, H-17′); 8.50 (s, 1H, H-17); 8.27 (br s, 1H, H-13′); 8.25 (br s, 1H, H-13); 7.99 (br d, J ∼ 8 Hz, 1H, H-11′); 7.96 (br d, J ∼ 8 Hz, 1H, H-11); 7.85 (two coalesced s', 2H, H-23,23′); 7.52 (t, J ∼ 8.0 Hz, 1H, H-10′); 7.49 (t, J ∼ 8.0 Hz, 1H, H-10); 7.44 (br d, J ∼ 8 Hz, 1H, H-9′); 7.39 (br d, J ∼ 8 Hz, 1H, H-9); 7.20 (two coalesced s', 2H, H-20,20′); 4.26 (m, 8H, H-25,25′,26,26′); 3.75 and 3.71 (m, 8H, H-27,27′,28′); 3.33 and 3.31 (2 × s, 2 × 6H, H-29,29′,30,30′). 13C-NMR (DMSO-d6): 169.1 (C-5); 156.7 (C-3); 156.6 (two coalesced lines, C-15,15′); 154.31 and 154.27 (C-21,21′); 153.2 (two coalesced lines, C-17,17′); 148.76 (two coalesced lines, C-22,22′); 147.59 and 147.55 (C-19,19′); 140.44 (two coalesced lines, C-12,12′); 129.9 (C-10′); 129.8 (C-10); 127.16 and 127.23 (C-9,9′); 126.4 (two coalesced lines, C-13,13′); 125.0 (C-11′); 124.3 (C-11); 121.0 (C-8); 119.6 (C-8′); 109.4 (two coalesced lines, C-24,24′); 108.7 (two coalesced lines, C-20,20′); 103.8 (two coalesced lines, C-23,23′); 82.4 (C-7,7′); 73.8 (C-6,6′); 70.60 and 70.57 (C-25,26′,25′,26′); 68.96 and 68.62 (C-27,28,27′,28′); 58.92 and 58.85 (C-29,30,29′,30′) ppm.
NMR data of 15: 1H-NMR (DMSO-d6): 9.50 (s, 1H, H-14); 8.48 (s, 1H, H-17); 8.12 (br s, 1H, H-13); 7.89 (br d, J ∼ 8 Hz, 1H, H-11); 7.83 (s, 1H, H-23); 7.43 (t, J ∼ 8.0 Hz, 1H, H-10); 7.31 (br d, J ∼ 8 Hz, 1H, H-9); 7.19 (s, 1H, H-20); 4.26 (m, 4H, H-25,26); 3.75 and 3.71 (m, 4H, H-27,28); 3.33 and 3.31 (2 × s, 2 × 3H, H-29,30). 13C-NMR (DMSO-d6): 156.7 (C-2); 156.6; (C-15); 154.19 (C-21); 153.2 (C-17); 148.68 (C-22); 147.5 (C-19); 140.4 (C-12); 129.7 (C-10); 127.6 (C-9); 126.3 (C-13); 124.1 (C-11); 121.3 (C-8); 109.4 (C-24); 108.5 (C-20); 103.7 (C-23); 82.4 (C-7); 73.8 (C-6); 70.60 and 70.57 (C-25,26); 68.96 and 68.62 (C-27,28); 58.92 and 58.85 (C-29,30) ppm.
For compounds 14 and 15 the signals from nuclei H-20,20′, H-23,23′, H-25,25′-H-30,30′ and C-19,19′-C-30,30′ are exactly coalesced or almost completely overlapped.
Protocol 1: the cells were grown to confluency and were distributed into 96-well tissue culture plates with an initial cell number of 5.0 × 103 per well. After 24 h of incubation at 37 °C, the cells were treated with the compounds in 200 μL final volume containing 1.0 v/v% DMSO. The cells were incubated with the compounds at 0.4–50 μM concentration range for 20 h, whereas control cells were treated with serum-free medium (RPMI-1640) only or with DMSO (c = 1.0 v/v%) at 37 °C for 20 h. After incubation, the cells were washed twice with serum-free RPMI-1640 medium. To determine the in vitro cytostatic effect, the cells were further cultured for 72 hours in 10% serum-containing medium. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution, MTT-solution, (45 μL, 2 mg mL−1, final concentration: 0.37 mg mL−1) was added to each well. The respiratory chain60,61 and other electron transport systems62 reduce MTT and thereby form non-water-soluble violet formazan crystals within the cell.63
The amount of these crystals can be determined spectrophotometrically and serves as an estimate for the number of mitochondria and hence the number of living cells in the well.64 After 3 hours of incubation the cells were centrifuged for 5 minutes at 900 g and the supernatant was removed. The obtained formazan crystals were dissolved in DMSO (100 mL) and optical density (OD) of the samples was measured at λ = 540 and 620 nm, respectively, using ELISA Reader (iEMS Reader, Labsystems, Finland). OD620 values were subtracted from OD540 values. The percent of cytostasis was calculated by using the following equation:
Cytostatic effect (%) = [1 − (ODtreated/ODcontrol)] × 100 |
Values ODtreated and ODcontrol correspond to the optical densities of the treated and the control cells, respectively. In each case, two independent experiments were carried out with 4 parallel measurements. The 50% inhibitory concentration (IC50) values were determined from the dose-response curves. The curves were defined using Microcal™ Origin2018 software: cytostasis was plotted as a function of concentration, fitted to a sigmoidal curve, and based on this curve, the half-maximal inhibitory concentration (IC50) value was determined. IC50 represents the concentration of a compound that is required for 50% inhibition in vitro and expressed in micromolar units.
Protocol 2 and 3: cells were divided into 96 well tissue-culture plates in 200 μL culture medium with the initial cell number of 5000 cells per well. The compounds were dissolved in DMSO and then diluted with fresh culture medium (final DMSO concentration was 1% in each well) and they were added to the cells at 0.016, 0.08, 0.4, 2.0 and 10 μM final concentration. Cells were incubated with the compounds at 37 °C for 72 hours (protocol 2). The same layout of plates was parallelly treated – culture medium was removed, then compounds dissolved in medium containing 2.5% FBS were added to the wells, without washing – 3 times, in every 24 hours (protocol 3). After that, cell viability was determined by MTT-assay using 0.37 mg mL−1 final concentration of MTT, in each well. After 3 hours of incubation with MTT the absorbance was measured with ELISA-reader (Labsystems MS Reader) at 540 nm and 620 nm as reference wavelengths. IC50 values were determined from the dose-response curves using the same method as described in Protocol 1.
Footnote |
† Electronic supplementary information (ESI) available: NMR and MS spectra; geometric parameters of molecules from XRD measurements; tables containing parameters of optimisation of reaction conditions. CCDC 2034611–2034616. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d1ra05095h |
This journal is © The Royal Society of Chemistry 2021 |